Topics

FDA Approves Luspatercept to Treat Beta Thalassemia–Associated Anemia

19:00 EST 7 Nov 2019 | Cancer Networks

The agency approved the first and only FDA-approved erythroid maturation agent to treat anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.

Original Article: FDA Approves Luspatercept to Treat Beta Thalassemia–Associated Anemia

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Luspatercept to Treat Beta Thalassemia–Associated Anemia"

Quick Search